FACS analyses of hematopoietic tissues from B6-Ptprc donor (CD45.1)/EPAS1 null or wild-type littermate recipient (CD45.2) mice
Tissue and epitope . | WT ± SEM . | KO ± SEM . |
|---|---|---|
| Bone marrow | ||
| CD45.1, % total cells | 47.2 ± 7.8* | 26.4 ± 11.4* |
| CD45.2, % total cells | 46.0 ± 6.8* | 66.6 ± 11.2* |
| CD3, % CD45.1 | 2.8 ± 0.5 | 2.6 ± 0.3 |
| B220, % CD45.1 | 20.3 ± 1.5 | 19.2 ± 2.2 |
| MAC-1, % CD45.1 | 74.4 ± 2.5 | 69.6 ± 4.7 |
| GR-1, % CD45.1 | 64.0 ± 3.3 | 61.2 ± 4.0 |
| TER-119, % CD45.1 | 3.5 ± 0.4 | 4.1 ± 1.5 |
| C-KIT, % CD45.1 | 2.5 ± 0.6 | 5.6 ± 3.5 |
| SCA-1, % CD45.1 | 7.0 ± 1.7 | 12.5 ± 3.5 |
| Spleen | ||
| CD45.1, % total cells | 52.1 ± 3.6 | 41.3 ± 5.1 |
| CD45.2, % total cells | 35.2 ± 3.5 | 49.4 ± 7.9 |
| CD3, % CD45.1 | 40.2 ± 2.6 | 48.7 ± 9.3 |
| B220, % CD45.1 | 60.2 ± 7.0 | 50.6 ± 9.7 |
| NK 1.1, % CD45.1 | 6.2 ± 0.1 | 5.9 ± 3.0 |
| Thymus | ||
| CD45.1, % total cells | 83.8 ± 7.8 | 71.1 ± 13.3 |
| CD45.2, % total cells | 11.7 ± 5.6 | 11.5 ± 5.0 |
| CD8, % CD45.1 | 88.3 ± 1.8 | 90.7 ± 1.4 |
| CD4, % CD45.1 | 94.5 ± 0.6 | 94.9 ± 1.0 |
| Lymph node | ||
| CD45.1, % total cells | 58.8 ± 4.0 | 51.7 ± 4.6 |
| CD45.2, % total cells | 40.7 ± 4.1 | 47.9 ± 4.4 |
| B220, % CD45.1 | 11.3 ± 3.8 | 15.4 ± 4.8 |
| CD8, % CD45.1 | 30.4 ± 2.3** | 20.7 ± 2.5** |
| CD4, % CD45.1 | 56.1 ± 4.0 | 52.6 ± 4.1 |
| Peripheral blood | ||
| CD45.1, % total cells | 65.8 ± 6.7** | 50.1 ± 6.7** |
| CD45.2, % total cells | 29.8 ± 4.4** | 48.1 ± 7.0** |
| MAC-1, % CD45.1 | 13.3 ± 2.4 | 9.6 ± 2.8 |
Tissue and epitope . | WT ± SEM . | KO ± SEM . |
|---|---|---|
| Bone marrow | ||
| CD45.1, % total cells | 47.2 ± 7.8* | 26.4 ± 11.4* |
| CD45.2, % total cells | 46.0 ± 6.8* | 66.6 ± 11.2* |
| CD3, % CD45.1 | 2.8 ± 0.5 | 2.6 ± 0.3 |
| B220, % CD45.1 | 20.3 ± 1.5 | 19.2 ± 2.2 |
| MAC-1, % CD45.1 | 74.4 ± 2.5 | 69.6 ± 4.7 |
| GR-1, % CD45.1 | 64.0 ± 3.3 | 61.2 ± 4.0 |
| TER-119, % CD45.1 | 3.5 ± 0.4 | 4.1 ± 1.5 |
| C-KIT, % CD45.1 | 2.5 ± 0.6 | 5.6 ± 3.5 |
| SCA-1, % CD45.1 | 7.0 ± 1.7 | 12.5 ± 3.5 |
| Spleen | ||
| CD45.1, % total cells | 52.1 ± 3.6 | 41.3 ± 5.1 |
| CD45.2, % total cells | 35.2 ± 3.5 | 49.4 ± 7.9 |
| CD3, % CD45.1 | 40.2 ± 2.6 | 48.7 ± 9.3 |
| B220, % CD45.1 | 60.2 ± 7.0 | 50.6 ± 9.7 |
| NK 1.1, % CD45.1 | 6.2 ± 0.1 | 5.9 ± 3.0 |
| Thymus | ||
| CD45.1, % total cells | 83.8 ± 7.8 | 71.1 ± 13.3 |
| CD45.2, % total cells | 11.7 ± 5.6 | 11.5 ± 5.0 |
| CD8, % CD45.1 | 88.3 ± 1.8 | 90.7 ± 1.4 |
| CD4, % CD45.1 | 94.5 ± 0.6 | 94.9 ± 1.0 |
| Lymph node | ||
| CD45.1, % total cells | 58.8 ± 4.0 | 51.7 ± 4.6 |
| CD45.2, % total cells | 40.7 ± 4.1 | 47.9 ± 4.4 |
| B220, % CD45.1 | 11.3 ± 3.8 | 15.4 ± 4.8 |
| CD8, % CD45.1 | 30.4 ± 2.3** | 20.7 ± 2.5** |
| CD4, % CD45.1 | 56.1 ± 4.0 | 52.6 ± 4.1 |
| Peripheral blood | ||
| CD45.1, % total cells | 65.8 ± 6.7** | 50.1 ± 6.7** |
| CD45.2, % total cells | 29.8 ± 4.4** | 48.1 ± 7.0** |
| MAC-1, % CD45.1 | 13.3 ± 2.4 | 9.6 ± 2.8 |
FACS profiles of bone marrow, splenic, thymic, and lymph node hematopoietic cells from EPAS1/HIF-2α null or wild-type littermate recipient (CD45.2+) mice reconstituted with B6-Ptprca donor (CD45.1+) BM HSCs. Statistical comparisons made pair-wise by 2-tailed t tests revealed significant findings at P ≤ .05 (*) or P ≤ .10 (**).